LIMN logo
LIMN NASDAQ US

Liminatus Pharma, Inc. - Class A Common Stock

Healthcare · Biotechnology Website · IPO May 2021
$0.18
▲ +$0.00 (+2.34%)
Vol 494K
2
Quality Score
fail
Mkt Cap
$16.5M
Beta
0.36
52W
$1–$34

Price Chart

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM)
P/E (TTM)
Net Margin
Gross Margin
D/E Ratio
Current Ratio 0.17 0.09 0.09 0.09 0.42

Key Ratios

ROA (TTM)
-95.3%
EPS (TTM)
$-0.20
52W High
$33.66
52W Low
$0.61
$0.61 52-Week Range $33.66

How does LIMN compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

LIMN AAPG ABEO ABOS ABP

LIMN valuation vs Biotechnology peers

P/E ratio
0% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
0% below peers (12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
0% below peers (2.5)
vs Peers
vs Industry
Overvalued
Div yield
0% below peers (0.0%)
vs Peers
vs Industry
Low yield

LIMN profitability vs Biotechnology peers

ROE
0% below peers (-67.3%)
vs Peers
vs Industry
Top tier
Net margin
0% below peers (-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
0% below peers (78.6%)
vs Peers
vs Industry
In line
ROA
-95.3%
104% below peers (-46.7%)
vs Peers
vs Industry
Weak

LIMN financial health vs Biotechnology peers

D/E ratio
0% below peers (0.0)
vs Peers
vs Industry
High debt
Current ratio
0.4
91% below peers (4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
63% below peers (1.0)
vs Peers
vs Industry
More volatile

LIMN fundamentals radar

LIMN Peer median Industry

LIMN profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

LIMN vs peers: key metrics

Latest News

No related news yet